Chapter from the book Advances in the Biology, Imaging and Therapies for Glioblastoma
Downloaded from: http://www.intechopen.com/books/advances-in-the-biology-imaging-and-therapies-for-glioblastoma
Assessment of Rodent Glioma Models Using Magnetic Resonance Imaging Techniques

Rheal A. Towner, Ting He, Sabrina Doblas and Nataliya Smith

Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation
Oklahoma City
U.S.A.

1. Introduction

There is a strong need to obtain precise surrogate biomarkers to improve the accuracy of diagnosis for gliomas, and to effectively evaluate therapeutic response. Often pre-clinical models of disease are used to develop diagnostic procedures and assess the effectiveness of a potential therapy. For gliomas, there are a variety of rodent models that have been investigated by numerous investigators over the past few decades, ranging from intracranial rodent glioma cell implantation models, intracranial human glioma xenografts, orthotopic implantation of human glioma stem cells, multipotent human glioblastoma stem-like neurosphere lines, transgenic mouse models, to viral-induced progenitor or stem cell derived glioma models. Tumor grades in these models vary from low to high grade tumors, with many of the high-grade glioma models sharing some of the characteristics of human grade IV glioblastoma multiforme (GBM). Many of the characteristic features of gliomas can be assessed diagnostically with in vivo imaging techniques such as magnetic resonance imaging (MRI). MRI has the capability of obtaining morphological/anatomical, functional, biophysical, molecular and metabolic information of a disease at various pathological stages of development. Tumor characteristics often associated with aggressive gliomas include an invasive growth pattern, angiogenesis, necrosis, hypoxia, edema, and alterations in major metabolic pathways. Morphological features, such as tumor size and position, infiltrative growth, hemorrhaging, necrotic lesions, edema, mass effect, heterogeneity, and cyst formation, can be followed using standard contrast-enhanced T1-weighted MR imaging or non-contrast T2-weighted imaging.

Although conventional MRI provides us with some indication about the nature of the lesion or tumor, it has limited sensitivity and specificity in determining histological type and grade, delineating margins and differentiating edema, as well as effectively evaluating therapeutic effects or side-effects. Incorporating some advanced MR techniques, such as MR angiography (MRA), perfusion-weighted MR imaging (PWI), diffusion-weighted MR imaging (DWI), MR spectroscopy (MRS), and molecular MRI (mMRI), may help to overcome some of those limitations. Angiogenesis associated with major blood vessels can be assessed using MR angiography, whereas perfusion-weighted imaging can be used to monitor angiogenesis associated with capillary vessels in tumors. Biophysical parameters such as water diffusion, as measured by diffusion-weighted imaging, have also provided
information regarding alterations in tissue structure associated with glioma tumors. An extension of the diffusion-weighted imaging technique is diffusion tensor imaging (DTI), which can provide information on white matter neuronal fiber tractography. MR spectroscopy can be used to assess alterations in tumor metabolites associated with glucose, bioenergetics, amino acid or lipid metabolism, for example. Many of these advanced MR techniques are used in a clinical setting. More recently, molecular MRI (mMRI) which incorporates a MRI contrast agent as a signaling molecule and an affinity component that targets specific tumor markers associated with tumor growth, angiogenesis, cell invasion, inflammation, or apoptosis, can be used to characterize in vivo molecular events associated with gliomas.

This review will focus on various glioma models that have been studied in vivo, with particular emphasis on MR image and/or spectroscopy evaluation of these models, and the use of MR image criteria (morphological, biophysical, molecular and metabolic) to evaluate therapeutic treatments. The aims are to: (1) provide an overview on current rodent glioma models being studied; (2) provide an overview regarding currently used MR methods, including advanced MR techniques (e.g. MRA, DWI, PWI, MRS and mMRI), relevant to glioma research; and (3) summarize studies that have used MR methods to evaluate therapeutic response in pre-clinical models for gliomas.

2. Human gliomas

Gliomas represent 40% of all primary central nervous system (CNS) tumors diagnosed. Among them, glioblastomas (GBM) are the most malignant, with a very poor survival time of about 15 months for most patients diagnosed with this grade IV brain tumor (CBTRUS 2011). High grade gliomas are the most common primary brain tumors in adults, and their malignant nature ranks them as the fourth largest cause of cancer death (Niclou et al., 2010).

There are four tumor grades for gliomas: Grade I which is a non-malignant, fairly circumscribed astrocytoma that is rare and appears in young adults; Grade II which are a more common diffusely infiltrating astrocytoma; Grade III which is an anaplastic astrocytoma; and Grade IV which is a glioblastoma multiforme (Niclou et al., 2010). Grades II-IV gliomas generally are found in the adult population, and often recur following current treatment options (including surgical resection, radiotherapy, and chemotherapy) (Niclou et al., 2010).

Grading and identification criteria that can be used to provide information regarding tumor behavior are cell proliferation (cellularity and mitotic activity), nuclear atypia, neovascularization and the presence of necrosis and/or apoptotic regions (Gudinaviciene et al., 2004). Grade II gliomas (also referred to as diffuse astrocytomas) and grade III gliomas (also referred to as anaplastic astrocytomas) only differ based on their mitotic activity, and this difference accounts for a substantial decrease in the 5-year survival for patients, from 47% to 29% (from grade II to III, respectively) (CBTRUS 2011). Grade IV gliomas (GBM) are often characterized by the presence of large necrotic areas (Gudinaviciene et al., 2004) and generally have a 3% 5-year survival (CBTRUS 2011).

3. Rodent models of gliomas

Animal models are often used when researching a disease and trying to understand how a particular pathological process occurs, as well as a means of studying the efficacy of
potential new therapies. This review will provide examples of commonly used and new experimental animal models for gliomas, which make up a large portion of primary brain tumors. The majority of models involve intracerebral implantation of rodent (rat or mouse) or human glioma cells into synergetic rats or mice, or immunocompromised rodents (e.g. nude or athymic rats or mice). There are also a limited number of transgenic mouse models for gliomas. One approach to better simulate a human tumor is to obtain human glioma neurospheres from patients during tumor resection, and then culture the cells prior to intracerebral implantation into immunocompromised rodents. Another recent approach is to implant non-replicating viruses that can stimulate neuronal stem cells to turn into glioma cells which develop into diffuse tumors similar to those found in high-grade or malignant gliomas called, glioblastoma multiforme (or GBM).

3.1 Intracerebral cell implantation models
Glioma cells (rat, mouse or human origin) are injected into the cerebral cortex of rats or mice (synergetic if cells are transplanted into the same species and strain that they were obtained from, or immune-compromised rats or mice if human cells are used) using a stereotaxic device for precise implantation into a brain region. As tumors grow over a period of 1-2 months, this model is considered a short-term model. Different cell lines varying in their degree of malignancy, such as rat C6, 9L/LacZ, F98 and RG2 cells, mouse GL261 cells and human U87 cells, provide a range of gliomas from moderately aggressive to GBM-like.

Many of these models have some characteristics associated with human gliomas, such as aggressive tumor growth, angiogenesis, and tumor necrosis (in a few models), however the diffuse nature of high-grade gliomas, glioblastoma multiforme (GBM), is not well represented. In many instances the intracerebrally-implanted rodent tumors have defined tumor boundaries, which do not represent the infiltrative nature of GBMs well. A comprehensive review that discusses the advantages and disadvantages of rat brain tumor models, most of them involving intracerebral implantation of rat glioma cells, is discussed in a paper by Barth and Kaur (2009).

The rat C6 cell line produces diffusively invasive astrocytomas (Barth, 1998; Barth and Kaur, 2009), which have been found to be similar to human glioma cells regarding the expression of genes mainly involved in tumor progression (Sibenaller et al., 2005). C6 gliomas were induced in an outbred Wistar rat strain repeatedly injected with methylnitrosourea (MNU), which makes it non-syngeneic in inbred strains, and increases its potential to evoke an alloimmune response (Barth and Kaur, 2009). As a result of some genetic similarities to human gliomas, the C6 model has been widely used as a GBM model for a number of years (Grobben et al., 2002; Barth and Kaur, 2009). The 9L/LacZ-derived tumors are aggressive and infiltrative, and are angiogenic (Plate et al., 1993), which are some of the characteristics associated with human GBM (Weizsaecker et al., 1981). Although the aggressive 9L/LacZ gliomas are highly invasive (Szatmori et al., 2006) and have extensive neovascularization (Plate et al., 1993), due to their pronounced immunogenicity (Barth, 1998) and the fact that they are classified as gliosarcomas (Sibenaller et al., 2005), makes these cells a poor choice for glioma studies. F98 gliomas are classified as anaplastic malignant tumors, which have an infiltrative pattern of growth, and also have attributes associated with human GBM (Barth, 1998; Barth and Kaur, 2009). The aggressive and invasive nature (Barth, 1998; Barth and Kaur, 2009) of RG2 tumors (Groothuis et al., 1983), as well as the highly tumorigenic human glioblastoma U87 MG cell line (Martens et al., 2006; Cheng et al., 1996), both mimics human
high-grade gliomas via inducing vascular alterations. U87 pcDNA3 and U87 IRE1 DN human glioma cells were selected as malignant glioma models that form highly versus poorly vascularized tumors, respectively (Drogat et al., 2007; Wehbe et al., 2010). GL261 cells give rise to quickly growing, and diffusively invasive intracranial tumors in C57BL/6 mice (Szatmori et al., 2006). RG2 and F98 glioma cell lines were both obtained from chemical induction as a result of administering ethylnitrosourea (ENU) to pregnant rats, where the progeny developed brain tumors that were isolated, and propagated and cloned in cell culture (Barth and Kaur, 2009). Human U87 cells are of high interest for angiogenesis studies (Cheng et al., 1996). The immunogenicity issue of the 9L/Lacz model can be resolved by using non-immunogenic models (e.g. RG2).

Xenograft models, induced by orthotopic (into native tumor sites) injection of primary tumor cells or tumor cell lines, represent the most frequently used in vivo cancer model systems for glioma research (Waerzeggers et al., 2010). Both cell culture and xenograft model systems lack the stepwise genetic alterations that are thought to occur during tumor progression, and often do not represent the genetic and cellular heterogeneity of primary tumors, as well as the complex tumor-stroma interaction (Waerzeggers et al., 2010). Genetically engineered mouse models (discussed below in the “Transgenic Mouse Models” section) better represent the causal genetic events and subsequent in situ molecular evolution, the tumor-stroma interactions, and consist of cellular subpopulations such as cancer stem cells (discussed further in the “Human Glioma Neurospheres” and “Viral-Induced Glioma Models” sections below), that occur in native tumors (Waerzeggers et al., 2010).

3.2 Chemical-induced model

Slow-growing, low- and high-grade, spontaneous gliomas can be generated with a chemically-induced model from the administration of ENU (Kish et al., 2001; Koestner, 1990). Transplacental ENU exposure of a pregnant female a day before gestation, results in the formation of low-grade oligodendrogliomas and mixed gliomas, with a tumor incidence approaching 100%, in rat pups at approximately 3-6 months of age (Koestner, 1990). In addition to oligodendrogliomas and mixed gliomas, unfortunately the ENU-induced model also results in the formation of meningiomas (Koestner et al., 1971), spinal cord tumors (Koestner et al., 1971) and other primitive neuroectodermal tumors (Vaquero et al., 1992), decreasing its potential as a reproducible model. In addition to the isolation of RG2 and F98 rat glioma cells from ENU induction, A15A5 neoplastic astrocytes have also been cloned (Davaki and Lantos, 1980).

3.3 Transgenic mouse models

As we are beginning to understand the genetic mutations associated with gliomas, it is possible to generate transgenic mouse models that have these genetic mutations. Recent findings suggest that brain tumors originate from neural stem or progenitor cells. Some examples of transgenic mutations include deletions of gene combinations, such as Rb/p53, Rb/p53/PTEN or PTEN/p53 (Jacques et al., 2010). pRb is a retinoblastoma protein, which is a tumor suppressor protein that is dysfunctional in many cancers. Rb controls excessive cell growth by inhibiting cell cycle progression until the cell is ready to divide (Chinnam and Goodrich, 2011; Lohmann, 2010). p53 which is also known as protein 53 is a tumor suppressor protein responsible for regulating the cell cycle (Kim et al., 2011; Maclaine and
Hupp, 2011; Muller et al., 2011). PTEN, which stands for phosphatase and tensin homolog, is a tumor suppressor gene also involved in the regulation of the cell cycle (Natsume et al., 2011; Alexiou and Voulgaris, 2010). Rb/p53 mice developed malignant tumors in approximately 9 months (Jacques et al., 2010). PTEN/Rb/p53 tumors had an appearance that was similar to the Rb/p53 tumors (Jacques et al., 2010). Deletion of Rb/p53 or Rb/p53/PTEN resulted in the formation of primitive neuroectodermal tumors (PNET), which alludes to the role of an initial Rb loss involved in driving the PNET phenotype (Jacques et al., 2010). It was found that targeted deletion of PTEN and p53 in subventricular zone (SVZ) stem cells resulted in glioma formation with a latency period of approximately 7-8 months (Jacques et al., 2010). The tumors from the recombination of PTEN/p53 were histologically infiltrative, diffuse, necrotic and had signs of micro-vascular proliferation, which are all characteristics of human high-grade gliomas (Jacques et al., 2010).

Another successful transgenic mouse model involves the deletion of the TP53 (tumor protein 53) gene (Trp53 null background), and over-expressing human PDGF (platelet-derived growth factor) under the control of the GFAP (glial fibrillary acidic protein) promoter, which developed tumors with human glioblastoma-like features and with the integrated development of PDGFRα+ tumor cells and PDGFRβ+ Nestin+ vasculature in 2-6 months (Hede et al., 2009). The tumor suppressor gene TP53 is either lost or commonly mutated in astrocytic brain tumors, and these TP53 alterations are often combined with excessive growth factor signaling via the PDGF/PDGFRα complex (Hede et al., 2009). PDGF is one of many growth factors that regulate cell growth and division, and has been found to be widely associated with malignant gliomas (Calzolari and Malatesta, 2010; Shih and Holland, 2006).

4. Human glioma neurospheres

GBM cancer-initiating cells have been found to mediate resistance to chemotherapy and radiation treatment, both used as follow-up therapies following surgical resection of the main tumor mass (Wei et al., 2010). Cells isolated from GBM that possess the capacity for self-renewal following radiation and chemotherapy, can form neurospheres when cultured in vitro (Wei et al., 2010). The glioma-associated cancer-initiating cells were found to express MHC-I (major histocompatibility I) but not MHC-II, CD-40 or CD80, which induces T-cell immune deficiency, and express the costimulatory inhibitory molecule, B7-H1, which plays a role in mediating immune resistance in gliomas and induces T-cell apoptosis (Wei et al., 2010). These neurospheres can be intracerebrally implanted into immune-compromised rodents to develop tumors in vivo, and therefore provide an experimental model that more closely resembles recurrent human GBM (radiation and chemotherapeutic resistant and induce immunosuppression) to evaluate new therapies. Another approach that takes into consideration the role of tumor-initiating stem cells, is to orthotopically implant tiny fragments of surgically-resected tumors, containing brain tumor stem cells within the glioblastoma tissue, into immunocompromised mice (xenograft model) brains with the use of a trocar system (Fei et al., 2010).

4.1 Viral-induced glioma models

Glial progenitor cells in the white matter and subventricular zone within the central nervous system were recently found to be the likely candidates for glioma-initiating cells (Assanah et
Intracerebral implantation of PDGFB-green fluorescent protein (GFP)-expressing retroviruses into rodents were found to induce tumors that closely resembled diffuse human malignant gliomas which have been challenging to treat (Assanah et al., 2006; Masui et al., 2010). This model involves the use of a viral vector that stimulates neuronal stem cells to become glioma cells by expressing PDGF, which is involved in generating tumor cells (Masui et al., 2010). These studies demonstrate that both adult white matter and glial progenitors generate gliomas, as well as recruit resident progenitors to proliferate within the mitogenic environment of a tumor, and therefore contributing to the heterogeneous mass of cells that make up a malignant glioma (Assanah et al., 2006; Masui et al., 2010). It was previously demonstrated that PDGF-B could play a dose-dependent role in glial tumorigenesis, where PDGFR (PDGF receptor) signaling via elevating levels of PDGF-B chain expression quantitatively regulates tumor grade, and that PDGF-B expression is required to sustain high-grade oligodendrogliomas (Shih et al., 2004). PDGF-B expression in tumor cells was elevated by removing inhibitory regulatory elements in the PDGFB mRNA and a retroviral delivery system (Shih et al., 2004). To generate tumors, DF1 cells transfected with RCAS (repeat with splice acceptor) retroviral vectors, generating a culture of virus-producing cells, were injected intracranially into N-tva transgenic mice (Shih et al., 2004). By inhibiting PDGFR activity, it was possible to convert tumors from high to low grade (Shih et al., 2004).

Another recent study involved intracranial injection of lentiviral vectors with GFAP (glial fibrillary acidic protein) or CMV (cytomegalovirus) vectors into compound LoxP-conditional mice, which resulted in K-RasV12 expression and loss of p16Ink4a/p19Arf, with or without concomitant loss of p53 or Pten (de Vries et al., 2010). Like GFAP, CMV is a promoter (de Vries et al., 2010). CMV-Cre injection into p53;Ink4a/Arf;K-RasV12 mice was particularly found to result in the formation of high-grade gliomas within 2-3 weeks that had invasiveness and blood-brain barrier functionality characteristics that are found in human high-grade gliomas (de Vries et al., 2010).

5. MRI methods to detect gliomas

Magnetic resonance imaging (MRI) techniques are becoming more commonly used to provide information on brain tumor growth, vasculature, biochemical metabolism, and molecular changes in preclinical models, as MRI is the optimal imaging tool as part of the diagnostic process for human gliomas. Conventional MRI techniques, such as T1- and T2-weighted imaging, contrast-enhanced T1-weighted imaging, dynamic contrast enhanced (DCE) imaging, and diffusion-weighted imaging (DWI) methods can provide useful information on tumor location and extent of growth, blood-brain barrier (BBB) disruption, brain invasiveness, regional blood flow and blood volume, and tumor cellularity, all of which are characteristics associated with glioma grade and prognosis in a clinical setting (Waerzeggers et al., 2010). Morphological MRI (T2-weighted or T1-weighted contrast-enhanced imaging) is used to provide information on tumor volumes and growth rates, which can be used to distinguish between tumor grades. Contrast-enhanced imaging can be used to assess BBB disruption, however this feature can be absent in diffuse infiltrative tumor regions or when assessing therapeutic treatment (Waerzeggers et al., 2010). DCE imaging can be used to follow tumor angiogenesis by measuring changes in tumor vascular permeability, vascular density and
vessel morphology (Waerzeggers et al., 2010), particularly regarding the capillary bed. Magnetic resonance angiography (MRA) is also used to provide information on tumor vasculature associated with angiogenesis, however it tends to be restricted to major blood vessels >50 microns in diameter (Doblas et al., 2010). Diffusion weighted imaging (DWI) has been used in cancer imaging to evaluate tumor cellularity and infiltration, as well as monitor therapeutic response (Kauppinen, 2002). Metabolic information can be obtained by monitoring tumor metabolites by a method called MR spectroscopy (MRS), or variations thereof, such as MR spectroscopic imaging (MRSI) or chemical shift imaging (CSI). Molecular alterations can be assessed with the use of targeting MR contrast agents which can specifically indicate levels of cancer biomarkers that may be elevated in malignant tumors. The development of targeted imaging ligands attached to MRI contrast agents allows the in vivo evaluation of tumor biology, such as tumor cell apoptosis, angiogenic blood vessels or the expression of specific tumor antigens or signaling pathways (Waerzeggers et al., 2010).

5.1 Tumor morphology
MRI is obtained on small animal MR imaging systems (7 - 11.7 Tesla), that can accommodate rodents such as mice and rats. MR images are obtained in multiple slices (0.5-1 mm thick) to visualize an entire tumor (Gartesier et al., 2010). Examples of rodent tumor models for gliomas (e.g. rat C6 and RG2 models, and mouse GL261 model) are shown in Figure 1, depicting heterogeneous tumors (right cerebral cortex, upper regions) following intracerebral (orthotopic) implantation of rat or mouse glioma cells (Doblas et al., 2010).

From the multiple image slices through a tumor, tumor volumes can be measured, and the growth rate can be calculated from multiple imaging sessions over several days, weeks or months (as shown in Figure 2). Tumor areas are traced in multiple slices to calculate tumor volumes, which can be used to determine tumor growth and doubling times (Doblas et al., 2008, 2010; Garteiser et al., 2010). Robust tumor volume determinations can be made by using manual or automated segmentation techniques, which can be used to delineate tumor margins on the basis of signal intensity differences from surrounding brain tissue (Waldman et al., 2009).

Fig. 1. MR images of rodent gliomas. T2-weighted images of the rat C6 (A; 18 days following intracerebral implantation of cells) and RG2 (B; 13 days following cell implantation), and the mouse GL261 (C; 26 days following cell implantation) glioma models. Tumors appear as heterogeneous regions in the upper right area of the cerebral cortex regions.
Fig. 2. MR images used to calculate tumor volumes and tumor growth. T$_2$-weighted images of a mouse GL261 glioma at 14 (A), 23 (B) and 26 days (C) following intracerebral implantation of cells. Tumors are outlined (white ellipses). (D) Calculated GL261 tumor volumes which follow an exponential increase over time.

Fig. 3. Determination of necrotic volumes from MR image-observed tumors. (A) T$_2$-weighted MR image of a GL261 mouse glioma at 23 days following intracerebral implantation of cells. Note dark void regions in the heterogeneous tumor which are necrotic lesions. (B) Necrotic volumes from tumors can be measured (n=5; mean±S.D.). (C) Corresponding histological slide depicting necrosis in a GL261 tumor.

Tumor morphology can also provide information on tumor invasiveness and necrotic lesions. Necrotic lesions are depicted as dark void regions in a tumor (as shown in Fig. 3A), of which volumes (e.g. Fig. 3B) can be measured from multiple slices (Towner et al., 2010a). A comparison between the orthotopic rat glioma models, C6 and RG2, and the chemical
ENU-induced model, indicated that percent necrosis was highest in the ENU model, compared to RG2, and least in the C6 model (Towner et al., 2010a). Although the ENU-induced model is used to generate low-grade gliomas, it generates a heterogeneous population of glioma cells ranging from low- to high-grade, which contributes to the high incidence of necrotic lesions (Towner et al., 2010a). RG2 gliomas are known to be more aggressive, invasive and infiltrative than C6 gliomas (Groothuis et al., 1983). It has also been shown that RG2 gliomas have more diffuse margins at the interface to adjacent brain tissue, whereas C6 gliomas are less infiltrative with a distinct peritumoral region at the margin of the tumor (Doblas et al., 2010).

5.2 Tumor vasculature and ultrastructure

MR angiography can provide information on new blood vessels formed in tumors, a process known as angiogenesis which is required to maintain tumor growth. On small animal imaging MRI systems, the image in-plane resolution is >50 µm, which allows visualization of major blood vessels, arterioles and venules (Doblas et al., 2008, 2010). Quantitation of brain and tumor blood vessels can also be obtained, as well as measurements on blood vessel diameters and lengths (Doblas et al., 2008, 2010). An increase in total brain tumor blood volume was found to directly correlate with increasing tumor volumes during tumor growth (Doblas et al., 2010).

Quantification of the Brownian motion of water or diffusion within tissues can be measured through the apparent diffusion coefficient (ADC) which is obtained from diffusion-weighted imaging datasets. DWI yields ultrastructural information on cellular density and the extracellular matrix (Waldman et al., 2009; Sadeghi et al., 2003). Figure 5 shows an example of an ADC (Fig. 5 b) map in a C6 glioma-bearing rat brain, indicating higher ADC values in tumor tissue compared to contralateral ‘normal’ brain tissue (Garteiser et al., 2010). Temporal diffusion spectroscopy based on oscillating gradient spin-echo (OGSE) MRI was used to detect microscopic structural variations at the subcellular scale in C6 rat gliomas.

Fig. 4. MR angiography of a GL261 mouse glioma. (A) T2-weighted MR image of a GL261 glioma-bearing mouse brain (23 days following intracerebral implantation of cells.) (B) and (C), 3 dimensional angiograms of mouse brain blood vessels of a GL261 glioma-bearing mouse. Note altered vasculature on left-hand side in image B, as well as increased blood vessels (middle cerebral artery; depicted in left-mid-region of image C) in the tumor region.
Fig. 5. Diffusion- and perfusion-weighted imaging of a rat C6 glioma. (A) $T_2$-weighted MR image of a C6 glioma-bearing rat brain (20 days following intracerebral implantation of cells). (B) ADC map ($1 \times 10^{-4}$ mm$^2$/s) of a C6 glioma. Note higher ADC values in the tumor compared to ‘normal’ brain tissue. (C) Perfusion map (ml/(100g×min)) in a C6 glioma. Note decreased perfusion values in tumor tissue, compared to ‘normal’ brain tissue. (Colvin et al., 2008). An extension of DWI is diffusion tensor imaging (DTI) which obtains multidirectional images that can be used to obtain diffusional directionality information quantified as fractional anisotropy and displayed as dominant white fiber tract maps (tractography) ((Waldman et al., 2009). DTI was used to differentiate between two rat glioma models, which observed C6 glioma-induced ischemia of tumor-surrounding tissues, compared to the more infiltrative nature of F98 gliomas that penetrated into the corpus callosum (Asanuma et al., 2008a, 2008b).

Arterial spin labeling (ASL), a perfusion-weighted MRI method, uses a MR image signal based on the influx of magnetically labeled water into blood, as a means of quantifying absolute levels of cerebral blood flow (CBF) (Waldman et al., 2009). Another widely used perfusion method is dynamic susceptibility contrast MRI (DSC-MRI), which can be used to measure relative cerebral blood volume, relative cerebral blood flow (rCBF) and mean transit time from the kinetics resulting from a change in signal intensity following the bolus administration of a gadolinium (Gd)-based contrast agent (Waldman et al., 2009). Steady-state susceptibility contrast (SSC) images were used to obtain MRI vessel caliber index (VCI) measurements in a xenograft orthotopic U87 mouse brain tumor model, and were found to correlate closely with intravital optical microscopy (IVM) measurements (Farrar et al., 2010). Dynamic contrast-enhanced MRI (DCE-MRI) is commonly used to measure the permeability of the blood-brain-barrier (BBB). The transfer coefficient, $K_{trans}$ is associated with endothelial permeability, vascular surface area and blood flow ((Waldman et al., 2009). DCE-MRI revealed a significant change in tumor vessel permeability that was dependent on tumor progression and size in a GL26 orthotopic mouse glioblastoma model (Veeravagu et al., 2008). Fig. 5C depicts decreased perfusion values in a C6 glioma, compared to contralateral ‘normal’ brain tissue, obtained using the ASL method. Perfusion values were found to be increased in the more aggressive RG2 rat glioma compared to C6 (Towner et al., 2010a), which is associated with increased vascular proliferation in this model. The increased perfusion in the RG2 model was also correlated with increased capillary vascularity visualized in 3D confocal microscopy fluorescence images, as well as more diffuse and smaller blood vessels observed by MRA, compared to the C6 model (Towner et al., 2010a). A study by Valable et al. demonstrated that there was a slight reduction in vessel density in the tumor center within RG2 gliomas compared to a more increased reduction in vessel density within C6 gliomas, which was characterized by an increased blood volume fraction, and a
smaller relative increase in vessel size index in the RG2 tumor (Valable et al., 2008). The vessel density eventually decreased with increasing tumor cell proliferation (Valable et al., 2008). It was thought that early expression of Ang-2, MMP-2 and MMP-9, which has been found in C6 gliomas, could account for the destabilization of vessel walls and a reduction in vessel density during C6 tumor growth (Valable et al., 2008).

5.3 Tumor metabolism
Magnetic resonance spectroscopy (MRS) is an MR method that allows regional metabolite levels to be measured in tumors compared to surrounding non-tumor tissue. Important metabolites that can be assessed by 1H-MRS in brain tumors include N-acetyl aspartate (NAA), total creatine (tCr), total choline (tCho), lactate, myo-inositol and mobile lipids associated with necrosis. Metabolite levels can be quantified as metabolite ratios or absolute concentrations, or analyzed using pattern recognition (Waldman et al., 2009). Figure 6 depicts an example of regional MR spectra obtained in a rat C6 glioma within tumor and contralateral ‘normal’ brain tissues. Glioma tissue has characteristic increased mobile lipid signals at 1.3 and 0.9 ppm, as well as decreased NAA, tCr and tCho, compared to surrounding ‘normal’ brain tissue. Metabolites measured by MRS can provide information on brain tissue status, such as (1) NAA being a marker of healthy neuronal integrity, which is compromised within brain tumors, (2) choline-containing compounds being associated with cell membrane turnover, (3) creatine-containing compounds being associated with the cellular energy status, (4) lactate being linked to anaerobic respiration, and (5) mobile lipids resulting from intracellular lipid droplets and necrosis (Waldman et al., 2009). Spatially resolved 1H-MRS was used to reveal significantly decreased levels of NAA and tCr and increased lactate (or lipids) in intracerebral rat C6 gliomas, compared to the contralateral hemisphere (Ross et al., 1992; Terpstra et al., 1996). In F98 rat gliomas there were detected increases in tCho, myo-inositol and lipids, as well as the absence of a NAA signal (Gyngell et al., 1994).

Fig. 6. MR spectroscopy of a rat C6 glioma. Regional (PRESS; point-resolved spectroscopy; 3×3×3 mm³ or 27 µl volume) was obtained in tumor (right region in T2-weighted; bottom spectrum) and ‘normal’ (left region; top spectrum) brain tissues (19 days post-intracerebral implantation of C6 cells). Peak assignments: (1) tCho (total choline), (2) tCr (total creatine), (3) NAA (N-acetyl aspartate), (4) methylene (-CH₂-)ₙ lipid hydrogens, and (5) methyl (-CH₃) lipid hydrogens.
Other atomic nuclei, other than $^1$H, have also been used to assess $^{13}$C and $^{19}$F containing compounds in rodent gliomas. Hyperpolarized $^{13}$C MR metabolic imaging was used to follow the metabolism of hyperpolarized [1-(13)C]-pyruvate to lactate in rats with human glioblastoma xenografts (U-251 MG and U-87 MG), indicating higher levels in tumor versus normal brain tissue, and variations between tumor models (Park et al., 2010). Rat 9L glioma cells labeled with perfluoro-15-crown-5-ether ex vivo and implanted into rat striatum was used to measure intracellular partial pressure of oxygen (pO$_2$) (oximetry) in tumors (Kadayakkara et al., 2010).

5.4 Molecular imaging

The concept used in molecular imaging is to couple a targeting moiety (antibody or peptide targeted to a protein of interest) to a reporter molecule, such as a MRI contrast agent. Two commonly used MRI contrast agents are gadolinium (Gd)-based compounds, or iron oxide-based nanoparticles. The targeted MR probes are often injected via a tail-vein in rats or mice. The expression of cell adhesion molecules, such as integrins, has been found to be up-regulated during tumor growth and angiogenesis, and $\alpha_\beta_3$ expression which has been correlated with tumor aggressiveness, can be measured by MRI with targeted paramagnetic-labeled cyclic arginine-glycine-aspartic acid (RGD) peptides (Sipkins et al., 1998; Waerzeggers et al., 2010). Within U87MG xenograft tumors in nude mice, RGD-labeled ultrasmall superparamagnetic iron oxide (USPIO) probes were found to accumulate only within the neovasculature associated with tumors, but not within tumor cells (Kiessling et al., 2009). Tumor angiogenesis was also monitored via the expression of CD105 in F98 tumor-bearing rats with the use of Gd-DTPA liposomes targeted to CD105 (CD105-Gd-SLs) and MR imaging (Zhang et al., 2009). Combined MRI-coupled fluorescence tomography was used to assess epidermal growth factor receptor (EGFR) status in high- and low-EGFR expression tumor cells injected into nude mice by measuring the levels of a near-infrared fluorophore bound to a EGF ligand (Davis et al., 2010).

MR imaging probes have also been developed to monitor in vivo levels of other angiogenic proteins known to be over-expressed in malignant brain tumors, such as VEGF-R2 (vascular endothelial growth factor receptor 2) (He et al., 2010; Towner et al., 2010b); a tumor cell migration/invasion marker, such as c-Met, a tyrosine kinase receptor for the scatter factor (also known as the hepatocyte growth factor) (Towner et al., 2008, 2010c); and the inflammatory marker, inducible nitric oxide synthase (iNOS) (Towner et al., 2010a). With the use of a Gd-DTPA-albumin-anti-VEGFR2-biotin probe, regional differences in VEGFR2 levels were detected by MRI in vivo in a C6 glioma model, and probe-specificity for glioma tissue, particularly in the peri-tumor and peri-necrotic regions, was confirmed by tagging the biotin moiety of the probe in excised tissues with streptavidin-Cy3 (He et al., 2010). The control non-specific probe had rat IgG conjugated to the albumin, instead of the VEGFR2 antibody. A similar result was obtained when an aminated dextran-coated iron-oxide nanoparticles conjugated with a VEGFR2 antibody was used in a C6 glioma model, where distribution of the probe was mainly in the peri-tumor and peri-necrotic regions of the tumor (He et al., 2010). Confirmation of the presence of the nanoprobes was obtained by using Prussian blue stain for the VEGFR2-targeting iron oxide nanoparticles in excised tumor tissues (He et al., 2010).

Both Gd- and iron oxide-based probes were also developed to characterize c-Met levels in C6 gliomas. c-Met is a tumor marker that is over-expressed in many malignant cancers,
indicative of the invasive nature of a tumor. The distribution of c-Met was found to be more widely dispersed, but mainly concentrated in peri-tumor regions (Towner et al., 2008, 2010c). Figure 7A depicts the contrast-enhancement in a C6 glioma 3 hours following i.v. administration of a Gd-DTPA-albumin-anti-c-Met-biotin probe, and the corresponding perfusion map showing the increased uptake of the anti-c-Met probe in the peri-tumor regions (Towner et al., 2008).

iNOS levels were found to vary in different rat glioma models, as detected with a Gd-DTPA-albumin-anti-iNOS-biotin (anti-iNOS) probe, where percent MRI signal intensity changes were highest in the C6 tumor, compared to the RG2 and ENU-induced tumors (Towner et al., 2010a). Dynamic kinetic monitoring of the anti-iNOS probe indicated sustained uptake over 3 hours within tumor tissue regions, and no specific uptake of a control Gd-DTPA-albumin-IgG-biotin contrast agent within tumors (Towner et al., 2010a). Fluorescence imaging of the anti-iNOS probe by targeting the biotin moiety with streptavidin-Cy3, verified higher levels of probe uptake in C6 tumors versus RG2 gliomas, despite the increased perfusion and micro-vascularity detected in the RG2 tumors (Towner et al., 2010a). Confirmation of the presence of iNOS in glioma cell membrane, but not in normal astrocytes, was obtained by transmission electron microscopy of gold-labeled anti-iNOS antibodies (Towner et al., 2010a).

![Fig. 7. Molecular MR imaging of c-Met levels in a rat C6 glioma. (A) T1-weighted MR image 3 hours following i.v. administration of a Gd-DTPA-albumin-anti-c-Met-biotin probe. Note contrast enhancement in peri-tumor regions. (B) Perfusion map depicting distribution of the anti-c-Met probe. (C) Illustration of the Gd-DTPA-albumin-anti-c-Met-biotin probe, with the antibody (Ab) conjugated to albumin.](https://www.intechopen.com)

6. MRI evaluation of therapeutics against gliomas

Clinically, therapeutic response to surgical resection of gliomas, followed by radiation and chemotherapy, can be assessed by dynamic contrast-enhanced morphological MRI, increases in ADC values detected by DWI (Waerzeggers et al., 2010), decreases in the fractional tumor volume with a corresponding low relative cerebral blood volume detected by perfusion imaging, and/or reduced choline levels detected by MRS (Waldman et al., 2009). DCE-MRI was used to establish reduced Gd enhancement consistent with decreased vascular permeability following i.v. bevacizumab and carboplatin therapy in a human glioma (UW28) nude rat model (Jahnke et al., 2009). DCE-MRI using a high molecular weight contrast agent, albumin-Gd-DTPA, showed significantly increased Ktrans at the rim of
a VEGFR tyrosine kinase inhibitor (Vetanalib, PTK787) (anti-angiogenic) treated U251 gliomas in rats (Ali et al., 2010). Low-molecular-weight (Gd-DOTA; gadoterate meglumine) and macromolecular (P846, 3.5 kDa) MR contrast-enhanced imaging was used to assess the therapeutic effect of an anti-angiogenic compound, sorafenib, and microbeam radiation therapy in a 9L gliosarcoma model, finding that anti-angiogenic therapy decreased tumor vessel permeability to the macromolecular contrast agent (Lemasson et al., 2010). Dynamic perfusion MRI using iron oxide nanoparticles (ferumoxytol) was used to assess the vascular effects of an anti-angiogenic agent versus corticosteroid (dexamethasone) treatment in a U87MG human glioma model in athymic rats, which found that bevacizumab significantly decreased the tumor blood volume and decreased permeability as determined by an increased time-to-peak enhancement (Varallyay et al., 2009).

Morphological MRI, MR angiography and perfusion imaging were used to assess the therapeutic efficacy of nitrones in a rat C6 glioma model. It was demonstrated that the nitrosonitronate, 2-phenyl-2,2,6,6-tetramethylperidin-1-oxyl (PBN) was able to prevent and/or decrease tumor volumes (by ~60-fold, with significance, p<0.001), increase animal survival (>90%), and decrease total tumor blood volumes (by ~20%), in comparison to non-treated rats bearing C6 gliomas (Doblas et al., 2008). Another cohort of rats were intracerebrally implanted with C6 glioma cells, monitored for tumor growth, and when tumors reached a volume of ~50 mm$^3$ (approximately at 15 days post-intracerebral implantation of C6 glioma cells), PBN was administered (drinking water, 0.065% w/v) for a period of 25 days (Doblas et al., 2008). In the post-tumor treatment group, PBN was found to increase survival (40% of the treated rats, p<0.05), and decrease tumor volumes by ~2-fold, but was found to be non-significant (Doblas et al., 2008). Regarding post-tumor treatment, PBN was also found to not significantly affect blood tumor volumes, compared to non-treated rats (Doblas et al., 2008). It was concluded from these studies that PBN, when administered prophylactically, may have an effect on angiogenesis (Doblas et al., 2008).

Conversely, rats post-tumor treated with a PBN-derivative, OKN-007, were found to have significantly decreased tumor volumes (~3-fold, p<0.05), decreased the apparent diffusion coefficients (ADC) (~20%, p<0.05), and increased tissue perfusion rates (~60%, p<0.05) in tumors, compared to non-treated rats (Garteiser et al., 2010). OKN-007 was administered in the drinking water at 10 mg/kg/day starting when tumors had reached ~50 mm$^3$ in volume (about day 15 following intracerebral implantation of rat C6 glioma cells), and continued for a total of 10 days (Garteiser et al., 2010). One group of rats was euthanized after the 10 day treatment period, and a second group was monitored for an additional 25 days following the treatment period (Garteiser et al., 2010). In the cohort of animals that were treated for 10 days and then euthanized, percent survival was 100% (p<0.0001), whereas for the rats that were monitored for an additional 25 days the percent survival was greater than 80% (p<0.001) (Garteiser et al., 2010). Morphological MRI was used to calculate tumor volumes; diffusion-weighted imaging (DWI) was used to measure ADC, which assesses changes in water diffusion due to tissue structural alterations; and perfusion-weighted MRI (pMRI) was used to characterize tissue perfusion rates, which can provide information on alterations in the vascular capillary bed. Currently, the known pharmacological effects of the nitrones are primarily anti-inflammatory in nature. The parent nitrosonitronate compound, PBN, is known to inhibit (1) cyclooxygenase-2 (COX-2), (2) inducible nitric oxide synthase (iNOS), and (3) nuclear factor kappaB (NF-κB) (Floyd et al., 2008).
ADC values have been found to increase particularly in the early phase of anticancer therapies (Waerzeggers et al., 2010). Increases in ADC were found to be a time and dose sensitive marker of tumor (mouse xenografts) response to radiation therapy (Larocque et al., 2009). Contrast-enhanced MRI and DWI were used to characterize the vascular and cellular responses of GL261 and U87 gliomas to the tumor-vascular disrupting agent (VDA) 5,6-dimethylxantheno-4-acetic acid (DMXAA), which indicated significantly increased ADC values and the accumulation of contrast agent in treated tumors (Seshadri and Ciesielski, 2009). ADC and 3D T2*-weighted MRI measurements were used to validate ZD6474 (tyrosine kinase receptor inhibitor) inhibition on tumor growth and angiogenesis in EGFRvIII-expressing GBM8 gliomas (Yiin et al., 2010).

In a gene therapy-induced apoptosis (ganciclovir-treated herpes simplex thymidine kinase (HSV-tk) gene-transfected BT4C gliomas) study, combined DWI and 1H-MRS assessment was used to find interconnecting trends following therapeutic response in water diffusion and water-referenced concentrations of mobile lipids (Liimatainen et al., 2009). It is thought that apoptosis leads to an increase in 1H-MRS detectable mobile cholesterol compounds and unsaturated lipids resulting from the gene therapy-induced apoptosis (Hakumäki et al., 1999; Liimatainen et al., 2006, 2009). Amide proton transfer (APT) MRI was recently used to differentiate between different glioma models (SF188/V+, glioma and 9L gliosarcoma) and radiation-induced necrosis, where viable glioma tissue was hyperintense and radiation necrosis was hypointense to isointense (Zhou et al., 2011).

Iron oxide-based nanoparticles have recently been used as cell tracking agents, or non-targeted or targeted drug delivery. Magnetically-labeled cytotoxic T-cells were used as cellular probes and tracked by T2- and T2*-weighted MRI to differentiate glioma tissue from focal radiation necrosis in U-251 glioma-bearing rodents (Arbab et al., 2010). Focused ultrasound, which was used to permeabilize the blood-brain barrier and increase passive diffusion, was found to increase the delivery of drug (1,3-bis(2-chloroethyl)-1-nitrosourea and iron oxide nanoparticles that can be monitored with MRI, in a rat C6 glioma model (Chen et al., 2010). EGFRvIII antibody-conjugated iron oxide nanoparticles were used for convection-enhanced delivery and targeted therapy in glioblastoma mouse xenografts (U87DeltaEGFRvIII), and assessed by T2*-weighted MRI (Hadjipanayis et al., 2010).

7. Conclusions

There are several orthotopic rodent glioma models that have been used for several decades, and more recent transgenic, orthotopic xenograft neurosphere- or PDGF-B-expressing virus-induced models that better reflect the genetic and stem-cell involvement in gli tumorigenesis. It is important that appropriate glioma models are used that best represent our current knowledge of malignant glioblastomas in humans. Ideally the more recent models should be used if possible, however if an orthotopic syngeneic model is required, then the rat F98 or RG2, and mouse GL26(1) models seem to have some characteristics that resemble aspects of human glioblastomas, such as vascular proliferation, and aggressive and infiltrative tumor growth. The human U87 MG glioma cell xenograft model in athymic rodents also has beneficial characteristics resembling some aspects of human GBM. Choosing an appropriate model is particularly important when evaluating new anti-glioma therapies, as these models need to consider recurrent gliomas, possibly derived from cancer stem cells, which are radiation- and chemotherapy-resistant, and currently reflect the poor prognosis of high-grade gliomas in humans.
The evaluation of critical changes during tumorigenesis, as well as monitoring therapeutic responses, requires the use of appropriate imaging technologies. The focus of this review has been on the use of MR imaging and spectroscopy methodologies in pre-clinical rodent models for gliomas, many of which translate to clinical applications. DCE-MRI and ASL perfusion imaging, and MRA, can provide valuable information regarding morphological and dynamic alterations associated with tumor vasculature or angiogenesis. The ADC, as measured by DWI, and DTI, can assess tissue structural and organizational changes that occur during tumor formation. MR spectroscopy provides metabolic markers, such as NAA, tCr, tCho, lactate, and mobile lipids that undergo significant changes in concentrations during glial tumorigenesis, as a result of neuronal degradation (NAA), cell proliferation (tCho), anaerobic respiration (lactate), and necrosis (mobile lipids). These MRI-observable changes, such as tumor ADC, rCBF, $K_{\text{trans}}$, cerebral blood volume, and $^{1}$H-MRS detectable metabolites, can all be important criteria to assess therapeutic efficacy. Molecular MRI (mMRI) is a targeted approach that can be used to assess specific tumor molecular markers associated with angiogenesis, apoptosis, cell migration/invasion, metastasis, proliferation, or inflammation. Targeted probes can also be used to deliver therapeutic compounds to tumors that express high levels of a specific molecular marker, and if these probes have a Gd-, manganese (Mn)- or iron oxide-based construct, then they can be monitored by MRI.

8. References


contributes to angiogenesis and tumor growth in vivo. *Cancer Res.*, 67(14): 6700-07. ISSN:0008-5472


This book is intended for physicians and scientists with interest in glioblastoma biology, imaging and therapy. Select topics in DNA repair are presented here to demonstrate novel paradigms as they relate to therapeutic strategies. The book should serve as a supplementary text in courses and seminars as well as a general reference.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: